Cisplatin (CIS)-induced skeletal muscle atrophy is associated with mitochondrial dysfunction and increased levels of mitofusin-2 (Mfsn-2), tumor necrosis factor-alpha (TNF), and caspase-3 (Casp3), along with reduced meteorin-like (MtrnL) immunoreactivity, a marker linked to energy metabolism. This evidence concerns the gene CASP3 and in situ carcinoma.